AI Engines For more Details: Perplexity Kagi Labs You
Antipsychotic Effects: Quetiapine is primarily used to treat schizophrenia and bipolar disorder. It works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain, such as dopamine and serotonin, which are involved in mood regulation and psychosis.
Treatment of Bipolar Disorder: Quetiapine is approved for the treatment of both manic episodes and depressive episodes associated with bipolar disorder. It can help stabilize mood and reduce the frequency and severity of mood swings.
Management of Major Depressive Disorder (MDD): Quetiapine is sometimes used off-label as an adjunctive treatment for major depressive disorder, particularly in cases where other antidepressant medications have been ineffective.
Anxiolytic Effects: Quetiapine may have anxiolytic (anti-anxiety) properties and can help alleviate symptoms of anxiety disorders, such as generalized anxiety disorder (GAD), when used as an adjunctive treatment.
Improvement of Sleep Disturbances: Quetiapine is sometimes prescribed off-label for the management of sleep disturbances, including insomnia. It is thought to promote sleep by blocking histamine receptors in the brain.
Maintenance Treatment: Quetiapine may be used as a maintenance treatment to prevent the recurrence of mood episodes in patients with bipolar disorder who have responded well to initial treatment.
Off-Label Uses: Quetiapine is sometimes used off-label to manage other conditions, such as post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and borderline personality disorder (BPD), although the evidence supporting its efficacy in these conditions varies.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | 0 |
| ADHD | 3.9 | 0.3 | 12 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 2.3 | 1.9 | 0.21 |
| Allergies | 4.2 | 3.2 | 0.31 |
| Allergy to milk products | 1.3 | 1.6 | -0.23 |
| Alopecia (Hair Loss) | 0.8 | 0.8 | |
| Alzheimer's disease | 5.4 | 4.3 | 0.26 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.2 | 1 | 1.2 |
| Ankylosing spondylitis | 3.2 | 1.1 | 1.91 |
| Anorexia Nervosa | 1.4 | 2.3 | -0.64 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 3 | 2.6 | 0.15 |
| Atherosclerosis | 1.5 | 1.5 | 0 |
| Atrial fibrillation | 2.5 | 2.2 | 0.14 |
| Autism | 6 | 7.1 | -0.18 |
| Autoimmune Disease | 1.2 | 0.8 | 0.5 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2 | 2 | |
| Bipolar Disorder | 1.6 | 1.1 | 0.45 |
| Brain Trauma | 0.6 | 1.4 | -1.33 |
| Breast Cancer | 0.8 | 0.3 | 1.67 |
| Cancer (General) | 0.9 | 0.9 | 0 |
| Carcinoma | 3.6 | 1.7 | 1.12 |
| Celiac Disease | 2.1 | 2.6 | -0.24 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 3.6 | 3.6 | 0 |
| Chronic Kidney Disease | 2.1 | 1.3 | 0.62 |
| Chronic Lyme | 0.1 | 0.8 | -7 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.6 | 1.4 | 0.14 |
| Chronic Urticaria (Hives) | 1.3 | 0.9 | 0.44 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1.3 | 0.15 |
| Cognitive Function | 2.2 | 1.4 | 0.57 |
| Colorectal Cancer | 7.8 | 2.4 | 2.25 |
| Constipation | 1.8 | 0.7 | 1.57 |
| Coronary artery disease | 1.9 | 2.2 | -0.16 |
| COVID-19 | 6.1 | 6.5 | -0.07 |
| Crohn's Disease | 6.9 | 4 | 0.73 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.8 | 1.3 | -0.63 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 2.6 | 1.4 | 0.86 |
| Denture Wearers Oral Shifts | 1.3 | 1.3 | |
| Depression | 7.8 | 6.1 | 0.28 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 0.8 | 1.13 |
| Endometriosis | 2.2 | 1.6 | 0.38 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 2.5 | 2.2 | 0.14 |
| erectile dysfunction | 1.8 | 0.3 | 5 |
| Fibromyalgia | 2 | 1.3 | 0.54 |
| Functional constipation / chronic idiopathic constipation | 3.7 | 2.5 | 0.48 |
| gallstone disease (gsd) | 2.3 | 1.4 | 0.64 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.8 | 0.4 | 3.5 |
| Generalized anxiety disorder | 2.3 | 1.9 | 0.21 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.6 | 0.6 | 1.67 |
| Graves' disease | 1.6 | 2.1 | -0.31 |
| Gulf War Syndrome | 0.4 | 1.3 | -2.25 |
| Halitosis | 1.6 | 0.3 | 4.33 |
| Hashimoto's thyroiditis | 2.6 | 0.9 | 1.89 |
| Heart Failure | 2.8 | 2 | 0.4 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.7 | 0.6 | 0.17 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.6 | -0.2 |
| hyperglycemia | 2 | 2 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.6 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 3.4 | 3 | 0.13 |
| Hypothyroidism | 0.3 | 0.4 | -0.33 |
| Hypoxia | 2 | 0.4 | 4 |
| IgA nephropathy (IgAN) | 1.6 | 2.7 | -0.69 |
| Inflammatory Bowel Disease | 5 | 6.5 | -0.3 |
| Insomnia | 1.3 | 3 | -1.31 |
| Intelligence | 1.1 | 0.2 | 4.5 |
| Intracranial aneurysms | 1.4 | 0.3 | 3.67 |
| Irritable Bowel Syndrome | 5.3 | 4.5 | 0.18 |
| ischemic stroke | 2.7 | 1.7 | 0.59 |
| Liver Cirrhosis | 5.4 | 3.9 | 0.38 |
| Long COVID | 4.9 | 4.2 | 0.17 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.8 | 1 | -0.25 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.3 | 0.6 | 1.17 |
| ME/CFS with IBS | 0.3 | 0.7 | -1.33 |
| ME/CFS without IBS | 0.5 | 1.3 | -1.6 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.6 | 0.8 | -0.33 |
| Metabolic Syndrome | 4.5 | 6.1 | -0.36 |
| Mood Disorders | 8.2 | 5.3 | 0.55 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 4.7 | 3.7 | 0.27 |
| Multiple system atrophy (MSA) | 1.6 | 0.7 | 1.29 |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 2.2 | -2.2 | |
| Neuropathy (all types) | 0.7 | 1.7 | -1.43 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.4 | 3.5 | -0.03 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 7 | 5.8 | 0.21 |
| obsessive-compulsive disorder | 4.3 | 2.5 | 0.72 |
| Osteoarthritis | 2.5 | 1.4 | 0.79 |
| Osteoporosis | 2 | 1.6 | 0.25 |
| pancreatic cancer | 2.1 | 0.6 | 2.5 |
| Parkinson's Disease | 5.4 | 4.9 | 0.1 |
| Polycystic ovary syndrome | 5.9 | 3.1 | 0.9 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | 0 |
| primary biliary cholangitis | 0.6 | 1.2 | -1 |
| Primary sclerosing cholangitis | 2.8 | 1.9 | 0.47 |
| Psoriasis | 1.9 | 3.1 | -0.63 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.9 | 2.7 | 0.81 |
| Rosacea | 0.6 | 0.8 | -0.33 |
| Schizophrenia | 5.2 | 2.6 | 1 |
| scoliosis | 0.2 | 0.3 | -0.5 |
| Sjögren syndrome | 2.8 | 2 | 0.4 |
| Sleep Apnea | 1 | 1.3 | -0.3 |
| Slow gastric motility / Gastroparesis | 1 | 0.3 | 2.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.3 | 0.3 | 3.33 |
| Stress / posttraumatic stress disorder | 2.3 | 2.1 | 0.1 |
| Systemic Lupus Erythematosus | 3 | 2 | 0.5 |
| Tic Disorder | 1.5 | 0.4 | 2.75 |
| Tourette syndrome | 0.6 | 0.3 | 1 |
| Type 1 Diabetes | 3.9 | 2.9 | 0.34 |
| Type 2 Diabetes | 5.7 | 5.6 | 0.02 |
| Ulcerative colitis | 4.7 | 4.8 | -0.02 |
| Unhealthy Ageing | 2.7 | 2.3 | 0.17 |
| Vitiligo | 1.8 | 1 | 0.8 |
